

## Research Article

# Interferon Tau Affects Mouse Intestinal Microbiota and Expression of IL-17

Wenkai Ren,<sup>1,2</sup> Shuai Chen,<sup>1</sup> Liwen Zhang,<sup>3</sup> Gang Liu,<sup>1</sup> Tarique Hussain,<sup>1</sup> Xiao Hao,<sup>1</sup> Jie Yin,<sup>1</sup> Jieli Duan,<sup>1</sup> Bie Tan,<sup>1</sup> Guoyao Wu,<sup>4</sup> Fuller W. Bazer,<sup>4</sup> and Yulong Yin<sup>1</sup>

<sup>1</sup>Key Laboratory of Agro-Ecological Processes in Subtropical Region, Institute of Subtropical Agriculture, Chinese Academy of Sciences, Observation and Experiment Station of Animal Nutrition and Feed Science in South-Central China, Ministry of Agriculture, Hunan Provincial Engineering Research Center for Healthy Livestock and Poultry Production, Changsha, Hunan 410125, China

<sup>2</sup>University of the Chinese Academy of Sciences, Beijing 10008, China

<sup>3</sup>Jinan First People's Hospital, Shandong 250011, China

<sup>4</sup>Department of Animal Science, Texas A&M University, 2471 TAMU, College Station, TX 77843-2471, USA

Correspondence should be addressed to Bie Tan; [bietan@isa.ac.cn](mailto:bietan@isa.ac.cn) and Yulong Yin; [yinyulong@isa.ac.cn](mailto:yinyulong@isa.ac.cn)

Received 14 March 2016; Accepted 30 May 2016

Academic Editor: Fábio Santos Lira

Copyright © 2016 Wenkai Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was conducted to explore the effects of interferon tau (IFNT) on the intestinal microbiota and expression of interleukin 17 (IL-17) in the intestine of mice. IFNT supplementation increased microbial diversity in the jejunum and ileum but decreased microbial diversity in the feces. IFNT supplementation influenced the composition of the intestinal microbiota as follows: (1) decreasing the percentage of *Firmicutes* and increasing *Bacteroidetes* in the jejunum and ileum; (2) enhancing the percentage of *Firmicutes* but decreasing *Bacteroidetes* in the colon and feces; (3) decreasing *Lactobacillus* in the jejunum and ileum; (4) increasing the percentage of *Blautia*, *Bacteroides*, *Alloprevotella*, and *Lactobacillus* in the colon; and (5) increasing the percentage of *Lactobacillus*, *Bacteroides*, and *Allobaculum*, while decreasing *Blautia* in the feces. Also, IFNT supplementation decreased the expression of IL-17 in the intestines of normal mice and of an intestinal pathogen infected mice. In conclusion, IFNT supplementation modulates the intestinal microbiota and intestinal IL-17 expression, indicating the applicability of IFNT to treat the intestinal diseases involving IL-17 expression and microbiota.

## 1. Introduction

Interferon tau (IFNT) is produced by trophectoderm cells of conceptuses of ruminant species and is the maternal recognition of the pregnancy signal. Besides its critical roles in implantation and establishment of pregnancy in ruminants [1, 2], it has a plethora of physiological functions in various cell types such as macrophages, lymphocytes, and epithelial cells in humans and mice [3–5]. It is a type I interferon (IFN), which includes IFN alpha (IFNA), IFN beta (IFNB), IFN delta (IFND), and IFN omega (IFNW). After binding to a common receptor, IFNA receptor 1 (IFNAR1), and IFNAR2, type I IFNs affect the production of inflammatory cytokines such as interleukin- (IL-)  $1\beta$  and tumor necrosis factor  $\alpha$

(TNF- $\alpha$ ) [6, 7]. Thus, type I IFNs have widely recognized roles in inflammatory diseases, such as experimental allergic encephalomyelitis, multiple sclerosis, and spontaneous autoimmune diabetes [5, 8–10]. Notably, unlike other members of type I IFN family, IFNT has few adverse effects and low cytotoxicity even at high dosages [11, 12], suggesting its therapeutic potential as an alternative to other type I IFNs due to its anti-inflammatory effects. Recent compelling findings about the anti-inflammatory effects of IFNT include lower NLRP3 (nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3) inflammasome-driven IL- $1\beta$  secretion by human macrophages [4], mitigation of obesity-associated systemic tissue inflammation in mice [5], and promotion of Th2 biased immune response in mice [9].

The influence of IFNT on intestinal microbiota is unknown. The intestinal microbiota provides important benefits for the development of immune responses; however, the disturbances in the intestinal microbiota are associated with numerous chronic inflammatory diseases [13, 14]. Also, the effect of IFNT on expression of IL-17 in the intestine is not known. The potential effect of IFNT on expression of IL-17 is important as IL-17 promotes local chemokine production to recruit monocytes and neutrophils to sites of inflammation that leads to development and pathogenesis of various autoimmune diseases, including rheumatoid arthritis, psoriasis vulgaris, multiple sclerosis, and inflammatory bowel diseases [15, 16]. In this study, the intestinal microbiota and expression of IL-17 in the intestine were explored after two weeks of IFNT supplementation in a mouse model. The hypothesis is that IFNT supplementation alters intestinal microbiota and intestinal innate immunity in mouse model.

## 2. Materials and Methods

**2.1. Bacterial Strains.** This study used the *Escherichia coli* F4-producing strain W25K (hereafter referred as ETEC; O149:K91, K88ac; LT, STb, EAST), which was originally isolated from a piglet with diarrhea [17].

**2.2. IFNT Supplementation for Mice.** This study was conducted according to the guidelines of the Laboratory Animal Ethical Commission of the Chinese Academy of Sciences. ICR (Institute for Cancer Research) mice (six weeks of age) were purchased from SLAC Laboratory Animal Central (Changsha, China). The mice were housed individually in a pathogen-free animal vivarium (temperature, 25°C; relative humidity, 53%; 12 h dark/12 h light) and had free access to a standard rodent diet [18] and drinking water. After three days of accommodation, mice were assigned randomly into two groups (IFNT and control;  $n = 10/\text{group}$ ). Mice in the control group were fed the basal diet [18] and normal water, while mice in IFNT group were fed the basal diet and water containing recombinant IFNT (40 µg/L) for two weeks. The effective supplemental dosage of IFNT was established in previous study [5, 19]. At the end of the two weeks of experimental period, mice were sacrificed to collect contents of the lumens of the jejunum, ileum, and colon, as well as feces. The tissues including jejunum, ileum, and colon were also collected. Feed and water intake and body weight gain were monitored throughout the experiment. Samples were collected and stored at -80°C until processed.

**2.3. ETEC Infection of Mice.** After three days of accommodation to the conditions of the vivarium, ICR mice were assigned randomly into two groups (ETEC and IFNT+ETEC;  $n = 10/\text{group}$ ). Mice in IFNT+ETEC group were fed the basal diet and recombinant IFNT-supplemented water (40 µg/L) for two weeks, while mice in ETEC group were fed the basal diet and had normal water. After two weeks of feeding, mice in both groups were inoculated with  $10^8$  CFUs of ETEC W25K by oral gavage. At 6 hours after infection, all active mice were sacrificed to collect the jejunum, and the samples were stored at -80°C until processed.

**2.4. 16S rDNA Sequencing with Illumina MiSeq Sequencing.** DNA was extracted from the luminal contents of the jejunum, ileum and colon, and feces using the Qiagen QIAamp DNA Stool Mini Kit according to the protocol for isolation of DNA. Equal amounts of DNA from six different mice were pooled to generate one common sample for each type of sample (i.e., control versus IFNT, intestinal source, and feces). The V4-V5 region of the bacterial 16S ribosomal RNA gene was amplified by PCR using primers 515F 5'-barcode-GTGCCAGCMGCCGCGG-3' and 907R 5'-CCGTCAATTCMTTTRAGTTT-3', where barcode is an eight-base sequence unique to each sample. Illumina MiSeq sequencing and general data analyses were performed by a commercial company (Biotree, Shanghai, China). Miseq PE Libraries, Miseq Sequencing, and further analyses were based on previous work [20].

**2.5. RT-PCR.** Total RNA was isolated from liquid nitrogen frozen and ground jejunum, ileum, and colon using TRIZOL reagent (Invitrogen, USA) and then treated with DNase I (Invitrogen, USA) according to the manufacturer's instructions. Synthesis of the first strand (cDNA) was performed using oligo (dT) 20 and Superscript II reverse transcriptase (Invitrogen, USA). Primers were selected according to previous references [18, 21].  $\beta$ -actin was used as an internal control to normalize expression of target gene transcripts. The RT-PCR experiment was conducted according to previous studies [18, 21].

**2.6. Statistical Analyses.** Data shown are the means  $\pm$  the standard error of the mean (SEM). All statistical analyses for data were performed using SPSS 16.0 software (Chicago, IL, USA). Data were analyzed for the two treatment groups using Student's *t*-test. Differences of  $P < 0.05$  are considered significant.

## 3. Results

**3.1. IFNT Treatment Increases Feed Intake.** To investigate the effect of IFNT supplementation on mouse growth performance, feed intake, water intake, and body weight were monitored in IFNT-supplemented mice and control mice. With two weeks of IFNT supplementation, the averages for feed intake and water intake for IFNT-supplemented mice were significant ( $P < 0.05$ ) higher than for control mice (Figures 1(a) and 1(b)). However, IFNT supplementation had no significant effect on body weight of mice (Figure 1(c)).

**3.2. Changes in Bacterial Diversity of the Intestinal Microbiota Associated with IFNT Supplementation.** To explore the influence of IFNT supplementation on the intestinal microbiota, we analyzed the intestinal microbiota at end of two weeks of IFNT supplementation with 16S rDNA sequencing (Table 1). For microbiota in the jejunum, both Shannon and Simpson indices demonstrated that the diversity of microbiota in mice with IFNT supplementation was higher than the control mice, while the richness indices (Ace and Chao) suggested that the community richness in IFNT-supplemented and control mice was similar (Table 1). For the microbiota in the




FIGURE 1: IFNT supplementation has little effect on mouse body weight. (a) Average feed intake in the control and IFNT-supplemented mice ( $n = 10$ ). (b) Average water intake for control and IFNT-supplemented mice ( $n = 10$ ). (c) Relative body weight gains for control and IFNT-supplemented mice ( $n = 10$ ). Control mice were fed the basal diet and normal water, while mice in IFNT group were fed the basal diet and IFNT-supplemented water for two weeks. The asterisk (\*) indicates a statistically significant difference between two treatment groups ( $P < 0.05$ ). Data were analyzed using Student's  $t$ -test.

TABLE 1: Comparison of phylotype coverage and diversity estimation of the 16S rDNA gene libraries at 97% similarity from the pyrosequencing analysis.

Group	Number of readings	Number of OTU	Coverage	Richness estimator		Diversity index	
				Ace (95% CI)	Chao (95% CI)	Shannon (95% CI)	Simpson (95% CI)
Jejunum							
Control	12323	51	99.85%	78 (62–120)	70 (57–108)	1.06 (1.04–1.09)	0.52 (0.51–0.53)
IFNT	15653	64	99.95%	70 (66–83)	67 (65–78)	1.32 (1.30–1.35)	0.44 (0.43–0.45)
Ileum							
Control	12442	37	99.89%	52 (42–84)	57 (42–110)	0.73 (0.70–0.75)	0.70 (0.69–0.71)
IFNT	12264	66	99.79%	124 (99–167)	174 (101–400)	1.06 (1.03–1.08)	0.56 (0.55–0.56)
Colon							
Control	10327	298	99.58%	323 (311–343)	322 (309–349)	4.32 (4.29–4.35)	0.032 (0.030–0.034)
IFNT	11276	288	99.68%	306 (297–324)	313 (299–345)	4.32 (4.29–4.34)	0.027 (0.026–0.028)
Feces							
Control	12613	314	99.69%	336 (326–356)	339 (325–369)	4.39 (4.36–4.41)	0.026 (0.025–0.027)
IFNT	12493	312	99.58%	345 (331–371)	363 (337–414)	4.16 (4.13–4.19)	0.046 (0.044–0.049)

ileum, the diversity of microbiota (Shannon and Simpson) and richness indices (Ace) for mice with IFNT supplementation were higher than that of control mice (Table 1). For the microbiota in the colon, the diversity of microbiota (Shannon) and richness indices (Ace and Chao) were similar for IFNT-supplemented and control mice (Table 1). For the fecal microbiota, microbial diversity (Shannon and Simpson) in mice with IFNT supplementation was lower than for control mice, while the community richness (Ace and Chao) for IFNT-supplemented mice was similar to that for control mice (Table 1). Collectively, IFNT supplementation increases the diversity of microbiota in small intestine, while decreasing the diversity of microbiota in the feces.

**3.3. IFNT-Associated Alterations in Intestinal Microbiota.** The taxonomy of the intestinal microbiota was assessed using a taxon-dependent analysis and the RDP classifier. Seven phyla, including one candidate division (TM7), were found in the microbiota of the jejunum for all samples, including six phyla in the control mice and seven phyla in mice with IFNT supplementation. Eight phyla were found in the microbiota of the ileum of all samples, including six phyla in control mice and seven phyla in mice with IFNT supplementation. Ten phyla were found in the microbiota of the colon of all samples, including ten phyla in control mice and eight phyla in mice with IFNT supplementation. Ten phyla were found in the microbiota of the feces of all samples, including nine phyla in control mice and ten phyla in mice with IFNT supplementation.

For the jejunum, the two most abundant phyla in IFNT-supplemented mice, accounting for approximately 99% of all assigned sequence readings, were *Firmicutes* (94.5%) and *Bacteroidetes* (4.4%) (Figure 2(a)). In control mice, most abundant phyla were *Firmicutes* (97.6%) and *Bacteroidetes* (1.2%) (Figure 2(a)). For the ileum, the three most abundant phyla in IFNT-supplemented mice were *Firmicutes* (95.3%), *Candidate\_division\_TM7* (2.3%), and *Proteobacteria* (1.1%) (Figure 2(b)), while in control mice, they were *Firmicutes* (97.7%), *Proteobacteria* (1.5%), and *Bacteroidetes* (0.5%) (Figure 2(b)). For the microbiota in the colon, the three most abundant phyla in IFNT-supplemented mice were *Bacteroidetes* (72.2%), *Firmicutes* (23.0%), and *Proteobacteria* (4.1%) (Figure 2(c)), while they were *Bacteroidetes* (75.8%), *Firmicutes* (18.8%), and *Proteobacteria* (4.3%) in control mice (Figure 2(c)). For feces, the three most abundant phyla in IFNT-supplemented mice were *Bacteroidetes* (43.6%), *Firmicutes* (48.1%), and *Proteobacteria* (5.9%) (Figure 2(d)), while *Bacteroidetes* (53.2%), *Firmicutes* (39.2%), and *Proteobacteria* (5.3%) were most abundant for control mice (Figure 2(d)).

For the microbiota of the jejunum, the two most abundant genera in IFNT-supplemented mice, accounting for approximately 99% of all assigned sequence readings, were *Lactobacillus* (94.3%) and *S24-7\_norank* (4.9%) (Figure 3(a)). In control mice, they were *Lactobacillus* (97.3%) and *S24-7\_norank* (1.2%) (Figure 3(a)). For the ileum, the five most abundant genera in IFNT-supplemented mice were *Lactobacillus* (93.3%), *Candidatus-Saccharimonas* (2.3%), *Allobaculum* (1.2%), *Desulfovibrio* (1.1%), and *Enterorhabdus*

(0.6%), while they were *Lactobacillus* (97.3%), *Candidatus-Saccharimonas* (0.3%), *Allobaculum* (0.1%), *Desulfovibrio* (1.5%), and *Enterorhabdus* (0.07%) in control mice (Figure 3(b)). For the microbiota in the colon, IFNT supplementation increased the percentages of *Blautia* (7.0% versus 5.1%), *Bacteroides* (6.4% versus 3.7%), *Alloprevotella* (5.2% versus 1.3%), and *Lactobacillus* (4.0% versus 2.5%), compared with control mice (Figure 3(c)). For the fecal microbiota, IFNT supplementation increased the percentages of *Lactobacillus* (30.0% versus 16.7%), *Bacteroides* (3.3% versus 1.8%), and *Allobaculum* (4.5% versus 0.4%), while decreasing the *Blautia* (2.7% versus 6.5%) compared with control mice (Figure 3(d)).

Collectively, IFNT supplementation affects the composition of intestinal microbiota in mice, especially those for the colon and feces.

**3.4. IFNT Inhibits Expression IL-17 in the Intestine.** The effect of IFNT supplementation on activation of intestinal innate immunity in mice was further explored, focusing on the expression of polymeric immunoglobulin receptor (*Pigr*), *Mucin-4*, *Cryptidin-1*, *Cryptidin-4*, *Cryptidin-5*, *Il-17*, interferon gamma (*Ifn-γ*), lysozyme (*Lyz*), and *J-chain* in the jejunum, ileum, and colon [18, 21]. In the jejunum, IFNT supplementation significantly decreased the expression of *Cryptidin-5*, *Il-17*, *Ifn-γ*, and *Lyz*, while it had little effect on the expression of the other transcripts (Figure 4(a)). IFNT supplementation had no significant effect on the expression of those transcripts in the ileum of mice (Figure 4(b)). In the colon, IFNT supplementation significantly lowered the expression of *Cryptidin-1* and *Il-17* but had little effect on the expression of the other transcripts (Figure 4(c)). As IFNT supplementation decreased the expression of *Il-17* in the jejunum and colon, we further validated the effect of IFNT to decrease expression of IL-17 in ETEC infected mouse model. We found that ETEC infection promotes the *Il-17* expression in the mouse jejunum at 6 hours after infection (W. Ren and Y. Yin, unpublished results). After two weeks of IFNT supplementation, expression of *Il-17* in the jejunum was significantly lower in IFNT-supplemented mice, compared to that of nonsupplemented mice during ETEC infection (Figure 4(d)). Thus, IFNT supplementation reduces the expression of the inflammatory cytokine, IL-17, in the intestine of mice.

## 4. Discussion

In this study, although two weeks of IFNT supplementation increases the mouse feed and water intake but has little effect on body weight of mice. Results of a previous study revealed that IFNT supplementation (8 μg/kg BW/day) reduces body weight beginning at 3 weeks after IFNT supplementation in Zucker Diabetic Fatty rats, while lower dose of IFNT supplementation (4 μg/kg BW/day) has no significant effect on body weight during 8 weeks of IFNT treatment [19], indicating that the effect of IFNT on body weight depends on dosage and duration of IFNT treatment. However, in a mouse model with high-fat or low-fat diet, 12 weeks of IFNT treatment does not significantly affect body weight




FIGURE 2: Composition of the intestinal microbiota at the phylum level after IFNT supplementation. (a) The microbial composition in the jejunum. (b) The microbial composition in the ileum. (c) The microbial composition in the colon. (d) The microbial composition in the feces.

[5]. However, IFNT supplementation has little effect on feed intake and water intake in those investigations [4, 5].

In the present study, IFNT supplementation increases the microbial diversity in the jejunum and ileum, while decreasing the microbial diversity in the feces of mice. The gut microbiota affects numerous biological functions [22, 23] and is linked to the pathogenesis of various diseases, such as obesity [24], cancer [25], and liver cirrhosis [26]. The influence of the gut microbiome on host physiological functions and the pathogenesis of disease in hosts may result from the activities of the microbiome and its metabolic products [22]. It is widely accepted that body weight is associated with the composition

of intestinal microbiome and its metabolic capacity [27]. An increase in the relative proportion of *Firmicutes* is linked to obesity as *Firmicutes* ferments plant polysaccharides to produce short-chain fatty acids (SCFA), which provides additional energy for the host [28]. In phyla, IFNT supplementation decreases the percentage of *Firmicutes*, while increasing the *Bacteroidetes* in the jejunum and ileum. However, IFNT supplementation increases the percentage of *Firmicutes*, while decreasing the *Bacteroidetes* in the colon and feces. Thus, IFNT supplementation may regulate body weight and metabolism through effects on the intestinal microbiota. At the genus level, IFNT supplementation






FIGURE 3: The composition of the intestinal microbiota at the genus level after IFNT supplementation. (a) The microbial composition in the jejunum. (b) The microbial composition in the ileum. (c) The microbial composition in the colon. (d) The microbial composition in the feces.

decreases the *Lactobacillus* in the jejunum and ileum but increases the percentage of *Lactobacillus* and *Bacteroides* in the colon and feces. *Lactobacillus* has critical roles in the intestine to combat gastrointestinal bacterial pathogens and rotaviruses through competitive metabolic interactions and the production of antimicrobial molecules [29]. *Bacteroides* are known for their capacity to metabolize a wide variety of oligosaccharides from the intestinal luminal, such as xylan, starch, and host-derived glycans [30]. Thus, results of the present study suggest that IFNT supplementation affects those functions of the intestinal microbiome in mice.

IFNT supplementation inhibits intestinal expression of IL-17, which suggests that IFNT reduces intestinal inflammation. IL-17 is produced by inducible Th17 (iTh17) cells and natural Th17 (nTh17) cells and regarded as an intestinal proinflammatory cytokine [31]. IL-17 can activate nuclear factor  $\kappa$ B (NF- $\kappa$ B) transcription factors, extracellular signal-regulated protein kinase (ERK1 and ERK2), c-Jun N-terminal kinases (JNK-1 and JNK-2), and mitogen-activated protein kinases (p38 MAPKs) pathways, leading to upregulation of

expression of inflammatory cytokines, such as IL-6 and IL-1 [32]. Recent investigations have revealed that mammalian target of rapamycin (mTOR) is a critical signaling pathway for Th17 responses and IL-17 expression [33–37]. The mTOR signaling regulates IL-17 expression through hypoxia-inducible factor 1  $\alpha$  (HIF-1 $\alpha$ ) and ribosomal protein S6 kinase (S6K: S6K1 and S6K2) [37–40]. mTOR signaling activates HIF-1 $\alpha$ , which promotes IL-17 expression by activating ROR $\gamma$ t (a key transcriptional regulator of Th17 cells) and mediating degradation of Foxp3 (a key transcriptional regulator of Treg cells) [40]. S6K1 promotes the expression of early growth response protein 2 (EGR2), which then inhibits growth factor independent 1 transcription repressor (GFI1), which can negatively regulate expression of IL-17 without affecting *Rorc* expression [37, 38]. S6K2 (the nuclear-localized counterpart of S6K1) binds to ROR $\gamma$ t to promote nuclear translocation of ROR $\gamma$ t, which can complex with HIF- $\alpha$  and p300 in the nucleus to promote expression of IL-17 [37–39]. Thus, the underlying mechanism by which IFNT supplementation reduces intestinal IL-17 expression is of interest. The effect of




FIGURE 4: IFNT supplementation decreases expression of IL-17. (a) Expression of innate immune factors (*Pigr*, *Mucin-4*, *Cryptidin-1*, *Cryptidin-4*, *Cryptidin-5*, *Il-17*, *Ifn-γ*, *Lyz*, and *J-chain*) in the jejunum of mice ( $n = 10$ ). (b) Expression of innate immune factors in the ileum of mice ( $n = 10$ ). (c) Expression of innate immune factors in the colon of mice ( $n = 10$ ). (d) IFNT decreases expression of IL-17 in the jejunum of mice following ETEC infection ( $n = 10$ ). Data were analyzed using Student's  $t$ -test. An asterisk (\*) indicates a statistically significant difference between treatment groups ( $P < 0.05$ ).

IFNT supplementation to decrease expression of IL-17 in the intestine indicates a potential therapeutic application of IFNT to mitigate intestinal inflammatory diseases associated with expression of IL-17.

In conclusion, IFNT supplementation affects the diversity and composition of the intestinal microbiota and decreases expression of IL-17 in mice. The findings from this study are significant in understanding the physiological and immunological functions of IFNT in treatment of inflammatory diseases.

## Abbreviations

EGR2:	Early growth response protein 2
ERK:	Extracellular signal-regulated protein kinase
ETEC:	Enterotoxigenic <i>Escherichia coli</i>
FoxP3:	Forkhead box P3
GFI1:	Growth factor independent 1 transcription repressor
HIF-1α:	Hypoxia-inducible factor 1α
mTOR:	Mammalian target of rapamycin
RORγt:	Retinoic acid receptor-related orphan receptor gamma t
S6K:	Ribosomal protein S6 kinase.

## Competing Interests

The authors have no competing interests.

## Authors' Contributions

Wenkai Ren and Bie Tan designed the experiment; Wenkai Ren and Shuai Chen conducted the experiment; Wenkai Ren, Liwen Zhang, and Gang Liu analyzed the data; Tarique Hussain, Xiao Hao, Jie Yin, and Jieli Duan helped in the experiment; Wenkai Ren wrote the paper; Guoyao Wu, Fuller W. Bazer, and Yulong Yin revised the paper.

## Acknowledgments

This study was supported by National Natural Science Foundation of China (nos. 31330075, 31372326, and 31272463), National Key Basic Research Program of China (2013CB127302), and the National Science and Technology Ministry (2014BAD08B11).

## References

- [1] K. Brooks and T. E. Spencer, "Biological roles of interferon tau (IFNT) and type I IFN receptors in elongation of the ovine conceptus," *Biology of Reproduction*, vol. 92, article 47, 2015.

- [2] F. W. Bazer, W. Ying, X. Wang et al., "The many faces of interferon tau," *Amino Acids*, vol. 47, no. 3, pp. 449–460, 2015.
- [3] A. P. Alexenko, A. D. Ealy, and R. M. Roberts, "The cross-species antiviral activities of different IFN- $\tau$  subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential," *Journal of Interferon & Cytokine Research*, vol. 19, no. 12, pp. 1335–1341, 1999.
- [4] K. Hara, K. Shirasuna, F. Usui et al., "Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1 $\beta$  in macrophages," *PLoS ONE*, vol. 9, no. 12, Article ID e113974, 2014.
- [5] W. Ying, S. Kanameni, C.-A. Chang et al., "Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization," *PLoS ONE*, vol. 9, no. 6, Article ID e98835, 2014.
- [6] J. M. González-Navajas, J. Lee, M. David, and E. Raz, "Immunomodulatory functions of type I interferons," *Nature Reviews Immunology*, vol. 12, no. 2, pp. 125–135, 2012.
- [7] L. Boscá, O. G. Bodelón, S. Hortelano, A. Casellas, and F. Bosch, "Anti-inflammatory action of type I interferons deduced from mice expressing interferon  $\beta$ ," *Gene Therapy*, vol. 7, no. 10, pp. 817–825, 2000.
- [8] D. J. Gough, N. L. Messina, C. J. P. Clarke, R. W. Johnstone, and D. E. Levy, "Constitutive type I interferon modulates homeostatic balance through tonic signaling," *Immunity*, vol. 36, no. 2, pp. 166–174, 2012.
- [9] J. M. Soos, O. Stüve, S. Youssef et al., "Cutting edge: oral type I IFN- $\tau$  promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate," *The Journal of Immunology*, vol. 169, no. 5, pp. 2231–2235, 2002.
- [10] M. Inoue and M. L. Shinohara, "The role of interferon- $\beta$  in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis—in the perspective of inflammasomes," *Immunology*, vol. 139, no. 1, pp. 11–18, 2013.
- [11] C. H. Pontzer, F. W. Bazer, and H. M. Johnson, "Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1," *Cancer Research*, vol. 51, no. 19, pp. 5304–5307, 1991.
- [12] J. M. Soos, P. S. Subramaniam, A. C. Hobeika, J. Schiftenbauer, and H. M. Johnson, "The IFN pregnancy recognition hormone IFN- $\tau$  blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity," *Journal of Immunology*, vol. 155, no. 5, pp. 2747–2753, 1995.
- [13] B. Chassaing, O. Koren, J. K. Goodrich et al., "Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome," *Nature*, vol. 519, no. 7541, pp. 92–96, 2015.
- [14] C. E. West, H. Renz, M. C. Jenmalm et al., "The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies," *Journal of Allergy and Clinical Immunology*, vol. 135, no. 1, pp. 3–14, 2015.
- [15] W. Ouyang, J. K. Kolls, and Y. Zheng, "The biological functions of T helper 17 cell effector cytokines in inflammation," *Immunity*, vol. 28, no. 4, pp. 454–467, 2008.
- [16] T. Koga, C. M. Hedrich, M. Mizui et al., "CaMK4-dependent activation of AKT/mTOR and CREM- $\alpha$  underlies autoimmunity-associated Th17 imbalance," *Journal of Clinical Investigation*, vol. 124, no. 5, pp. 2234–2245, 2014.
- [17] W. Ren, G. Liu, J. Yin et al., "Draft genome sequence of enterotoxigenic *Escherichia coli* strain W25K," *Genome Announcements*, vol. 2, no. 3, Article ID e00593-14, 2014.
- [18] W. Ren, S. Chen, J. Yin et al., "Dietary arginine supplementation of mice alters the microbial population and activates intestinal innate immunity," *Journal of Nutrition*, vol. 144, no. 6, pp. 988–995, 2014.
- [19] C. D. Tekwe, J. Lei, K. Yao et al., "Oral administration of interferon tau enhances oxidation of energy substrates and reduces adiposity in Zucker diabetic fatty rats," *BioFactors*, vol. 39, no. 5, pp. 552–563, 2013.
- [20] J. Gibson, S. Shokralla, T. M. Porter et al., "Simultaneous assessment of the macrobiome and microbiome in a bulk sample of tropical arthropods through DNA metasytematics," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 22, pp. 8007–8012, 2014.
- [21] W. Ren, J. Duan, J. Yin et al., "Dietary l-glutamine supplementation modulates microbial community and activates innate immunity in the mouse intestine," *Amino Acids*, vol. 46, no. 10, pp. 2403–2413, 2014.
- [22] W.-J. Lee and K. Hase, "Gut microbiota-generated metabolites in animal health and disease," *Nature Chemical Biology*, vol. 10, no. 6, pp. 416–424, 2014.
- [23] S. Subramanian, S. Huq, T. Yatsunencko et al., "Persistent gut microbiota immaturity in malnourished Bangladeshi children," *Nature*, vol. 510, no. 7505, pp. 417–421, 2014.
- [24] F. F. Anhê, D. Roy, G. Pilon et al., "A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased *Akkermansia* spp. population in the gut microbiota of mice," *Gut*, vol. 64, no. 6, pp. 872–883, 2015.
- [25] P. Louis, G. L. Hold, and H. J. Flint, "The gut microbiota, bacterial metabolites and colorectal cancer," *Nature Reviews Microbiology*, vol. 12, no. 10, pp. 661–672, 2014.
- [26] N. Qin, F. Yang, A. Li et al., "Alterations of the human gut microbiome in liver cirrhosis," *Nature*, vol. 513, no. 7516, pp. 59–64, 2014.
- [27] P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, "An obesity-associated gut microbiome with increased capacity for energy harvest," *Nature*, vol. 444, no. 7122, pp. 1027–1031, 2006.
- [28] R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, "Microbial ecology: human gut microbes associated with obesity," *Nature*, vol. 444, no. 7122, pp. 1022–1023, 2006.
- [29] V. Liévin-Le Moal and A. L. Servin, "Anti-infective activities of Lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents," *Clinical Microbiology Reviews*, vol. 27, no. 2, pp. 167–199, 2014.
- [30] A. Marcobal and J. L. Sonnenburg, "Human milk oligosaccharide consumption by intestinal microbiota," *Clinical Microbiology and Infection*, vol. 18, supplement 4, pp. 12–15, 2012.
- [31] A. G. Shabgah, E. Fattahi, and F. Z. Shahneh, "Interleukin-17 in human inflammatory diseases," *Postepy Dermatologii i Alergologii*, vol. 31, no. 4, pp. 256–261, 2014.
- [32] S. H. Chang and C. Dong, "Signaling of interleukin-17 family cytokines in immunity and inflammation," *Cellular Signalling*, vol. 23, no. 7, pp. 1069–1075, 2011.
- [33] M. F. Gulen, Z. Kang, K. Bulek et al., "The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation," *Immunity*, vol. 32, no. 1, pp. 54–66, 2010.
- [34] J. S. Kim, T. Sklarz, L. B. Banks et al., "Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways," *Nature Immunology*, vol. 14, no. 6, pp. 611–618, 2013.



- [35] Y. Park, H.-S. Jin, J. Lopez et al., "TSC1 regulates the balance between effector and regulatory T cells," *The Journal of Clinical Investigation*, vol. 123, no. 12, pp. 5165–5178, 2013.
- [36] S. Nagai, Y. Kurebayashi, and S. Koyasu, "Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation," *Annals of the New York Academy of Sciences*, vol. 1280, no. 1, pp. 30–34, 2013.
- [37] W. Ren, J. Yin, J. Duan et al., "mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets," *European Journal of Immunology*, vol. 46, no. 2, pp. 291–299, 2016.
- [38] Y. Kurebayashi, S. Nagai, A. Ikejiri et al., "PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR $\gamma$ ," *Cell Reports*, vol. 1, no. 4, pp. 360–373, 2012.
- [39] L. Z. Shi, R. Wang, G. Huang et al., "HIF1 $\alpha$ -dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells," *The Journal of Experimental Medicine*, vol. 208, no. 7, pp. 1367–1376, 2011.
- [40] E. V. Dang, J. Barbi, H.-Y. Yang et al., "Control of T<sub>H</sub>17/T<sub>reg</sub> balance by hypoxia-inducible factor 1," *Cell*, vol. 146, no. 5, pp. 772–784, 2011.